Multiple Sclerosis Drug Price Increases Probed By House Oversight Panel Democrats
Reps. Cummings and Welch contact seven manufacturers of multiple sclerosis drugs with inquiries about persistent and significant annual price increases. The members suggest some firms are boosting prices in "lockstep."
You may also be interested in...
No European approval recommendation for Roche multiple sclerosis drug Ocrevus but the Swiss major tells Scrip it is hopeful of getting approval within four months.
Four contracts test approaches tying reimbursement to relapse rates and discontinuation of treatment. Payers involved include Harvard Pilgrim and Intermountain's SelectHealth.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.